Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AKCEA THERAPEUTICS, INC.AKCA · Entity 145982 | Director | July 13, 2017 | July 13, 2017 |
| IONIS PHARMACEUTICALS INCIONS · Entity 1182 | Director · Exec Chairman of the Board | January 26, 2021 | January 29, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AKCEA THERAPEUTICS, INC.
Report date July 13, 2017 · Filed July 13, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| No securities are beneficially owned.SEC Table I · non-derivative | Direct | 0 |
Reported balance
Holding disclosure · report date 2017-07-13 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 0 |
IONIS PHARMACEUTICALS INC
Report date January 26, 2021 · Filed January 29, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,021 |
Reported balance
After 2021-01-26 transaction · row 1
1 source rowRow 1 · 2021-01-26 · Sale · Disposed 28,333 · Balance 2,021 F1: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on January 2, 2020. F2: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.00 to $64.00, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) of this Form 4. |
| Common StockSEC Table I · non-derivative | IndirectBy wife | 3,111 |
Reported balance
Holding disclosure · report date 2021-01-26 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 3,111 |
| Common StockSEC Table I · non-derivative | IndirectBy trust | 494,391 |
Reported balance
Holding disclosure · report date 2021-01-26 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 494,391 |
Filing footnotes · ownership attribution and instrument terms
F1: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on January 2, 2020.
F2: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.00 to $64.00, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) of this Form 4.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 03, 2017 Filed Jul 3, 2017 21:34 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 13,462 | $0.00 Strike: $7.25 | $0.00 |
DisclosureSEC source: 0000874015-17-000042 · edgar.xml · derivative · entry 8 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,462 shares Expires 2019-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 03, 2017 Filed Jul 3, 2017 21:34 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 1,500 | $52.10 | $78,150.00 |
DisclosureSEC source: 0000874015-17-000042 · edgar.xml · nonDerivative · entry 6 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 3,062 F4 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 9/21/2015. F4 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 9/21/2015. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.79 to $52.30, inclusive. The reporting person's wife undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (5) on this Form 4. Read SEC document |
| July 03, 2017 Filed Jul 3, 2017 21:34 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 1,500 | $7.25 | $10,875.00 |
DisclosureSEC source: 0000874015-17-000042 · edgar.xml · nonDerivative · entry 5 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 4,562 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 9/21/2015. F4 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 9/21/2015. Read SEC document |
| July 03, 2017 Filed Jul 3, 2017 21:34 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 1,538 | $52.30 | $80,437.40 |
DisclosureSEC source: 0000874015-17-000042 · edgar.xml · nonDerivative · entry 4 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,014 F3 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 6/17/2016. F3 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 6/17/2016. Read SEC document |
| July 03, 2017 Filed Jul 3, 2017 21:34 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 1,538 | $14.69 | $22,593.22 |
DisclosureSEC source: 0000874015-17-000042 · edgar.xml · nonDerivative · entry 3 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,552 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 6/17/2016. F3 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 6/17/2016. Read SEC document |
| July 03, 2017 Filed Jul 3, 2017 21:34 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 13,462 | $52.08 | $701,100.96 |
DisclosureSEC source: 0000874015-17-000042 · edgar.xml · nonDerivative · entry 2 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,014 F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 9/21/2015. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 9/21/2015. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.79 to $52.30, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| July 03, 2017 Filed Jul 3, 2017 21:34 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 13,462 | $7.25 | $97,599.50 |
DisclosureSEC source: 0000874015-17-000042 · edgar.xml · nonDerivative · entry 1 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,476 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 9/21/2015. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 9/21/2015. Read SEC document |
| April 25, 2017 Filed Apr 27, 2017 22:03 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,500 | $0.00 Strike: $7.25 | $0.00 |
DisclosureSEC source: 0000874015-17-000030 · edgar.xml · derivative · entry 7 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 8,904 Underlying: Common Stock · 1,500 shares Expires 2019-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 25, 2017 Filed Apr 27, 2017 22:03 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $7.25 | $0.00 |
DisclosureSEC source: 0000874015-17-000030 · edgar.xml · derivative · entry 6 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,462 Underlying: Common Stock · 15,000 shares Expires 2019-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 25, 2017 Filed Apr 27, 2017 22:03 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 1,500 | $47.81 | $71,715.00 |
DisclosureSEC source: 0000874015-17-000030 · edgar.xml · nonDerivative · entry 4 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 3,062 F3 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 9/21/2015. F3 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 9/21/2015. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.80 to $47.82, inclusive. The reporting person's wife undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) on this Form 4. Read SEC document |
| April 25, 2017 Filed Apr 27, 2017 22:03 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 1,500 | $7.25 | $10,875.00 |
DisclosureSEC source: 0000874015-17-000030 · edgar.xml · nonDerivative · entry 3 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 4,562 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 9/21/2015. F3 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 9/21/2015. Read SEC document |
| April 25, 2017 Filed Apr 27, 2017 22:03 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 15,000 | $47.81 | $717,150.00 |
DisclosureSEC source: 0000874015-17-000030 · edgar.xml · nonDerivative · entry 2 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,014 F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 9/21/15 F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 9/21/15 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.80 to $47.82, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| April 25, 2017 Filed Apr 27, 2017 22:03 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 15,000 | $7.25 | $108,750.00 |
DisclosureSEC source: 0000874015-17-000030 · edgar.xml · nonDerivative · entry 1 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,014 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 9/21/15 F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 9/21/15 Read SEC document |
| April 19, 2017 Filed Apr 21, 2017 21:42 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 500 | $0.00 Strike: $7.25 | $0.00 |
DisclosureSEC source: 0000874015-17-000028 · edgar.xml · derivative · entry 7 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 10,404 Underlying: Common Stock · 500 shares Expires 2019-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 19, 2017 Filed Apr 21, 2017 21:42 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $7.25 | $0.00 |
DisclosureSEC source: 0000874015-17-000028 · edgar.xml · derivative · entry 6 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,462 Underlying: Common Stock · 5,000 shares Expires 2019-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 19, 2017 Filed Apr 21, 2017 21:42 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 500 | $43.25 | $21,625.00 |
DisclosureSEC source: 0000874015-17-000028 · edgar.xml · nonDerivative · entry 4 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 3,062 F2 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 9/21/2015. F2 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 9/21/2015. Read SEC document |
| April 19, 2017 Filed Apr 21, 2017 21:42 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 500 | $7.25 | $3,625.00 |
DisclosureSEC source: 0000874015-17-000028 · edgar.xml · nonDerivative · entry 3 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 3,562 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 9/21/2015. F2 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 9/21/2015. Read SEC document |
| April 19, 2017 Filed Apr 21, 2017 21:42 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 5,000 | $43.25 | $216,250.00 |
DisclosureSEC source: 0000874015-17-000028 · edgar.xml · nonDerivative · entry 2 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,014 F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 9/21/2015. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 9/21/2015. Read SEC document |
| April 19, 2017 Filed Apr 21, 2017 21:42 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 5,000 | $7.25 | $36,250.00 |
DisclosureSEC source: 0000874015-17-000028 · edgar.xml · nonDerivative · entry 1 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,014 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 9/21/2015. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 9/21/2015. Read SEC document |
| April 13, 2017 Filed Apr 13, 2017 23:24 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 500 | $0.00 Strike: $7.25 | $0.00 |
DisclosureSEC source: 0000874015-17-000026 · edgar.xml · derivative · entry 16 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 10,904 Underlying: Common Stock · 500 shares Expires 2019-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 13, 2017 Filed Apr 13, 2017 23:24 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 500 | $0.00 Strike: $10.29 | $0.00 |
DisclosureSEC source: 0000874015-17-000026 · edgar.xml · derivative · entry 15 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 0 Underlying: Common Stock · 500 shares Expires 2018-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 13, 2017 Filed Apr 13, 2017 23:24 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $7.25 | $0.00 |
DisclosureSEC source: 0000874015-17-000026 · edgar.xml · derivative · entry 14 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,462 Underlying: Common Stock · 10,000 shares Expires 2019-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 13, 2017 Filed Apr 13, 2017 23:24 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 500 | $41.30 | $20,650.00 |
DisclosureSEC source: 0000874015-17-000026 · edgar.xml · nonDerivative · entry 10 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 3,062 F3 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 9/21/2015. F3 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 9/21/2015. Read SEC document |
| April 13, 2017 Filed Apr 13, 2017 23:24 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 500 | $7.25 | $3,625.00 |
DisclosureSEC source: 0000874015-17-000026 · edgar.xml · nonDerivative · entry 9 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 3,562 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 9/21/2015. F3 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 9/21/2015. Read SEC document |
| April 13, 2017 Filed Apr 13, 2017 23:24 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 500 | $41.30 | $20,650.00 |
DisclosureSEC source: 0000874015-17-000026 · edgar.xml · nonDerivative · entry 8 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 3,062 F3 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 9/21/2015. F3 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 9/21/2015. Read SEC document |
| April 13, 2017 Filed Apr 13, 2017 23:24 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 500 | $10.29 | $5,145.00 |
DisclosureSEC source: 0000874015-17-000026 · edgar.xml · nonDerivative · entry 7 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 3,562 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 9/21/2015. F3 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 9/21/2015. Read SEC document |
| April 13, 2017 Filed Apr 13, 2017 23:24 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 10,000 | $41.30 | $413,000.00 |
DisclosureSEC source: 0000874015-17-000026 · edgar.xml · nonDerivative · entry 6 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,014 F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 9/21/2015. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 9/21/2015. Read SEC document |
| April 13, 2017 Filed Apr 13, 2017 23:24 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 10,000 | $7.25 | $72,500.00 |
DisclosureSEC source: 0000874015-17-000026 · edgar.xml · nonDerivative · entry 5 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,014 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 9/21/2015. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 9/21/2015. Read SEC document |
| April 12, 2017 Filed Apr 13, 2017 23:24 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $10.29 | $0.00 |
DisclosureSEC source: 0000874015-17-000026 · edgar.xml · derivative · entry 13 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 500 Underlying: Common Stock · 1,000 shares Expires 2018-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 12, 2017 Filed Apr 13, 2017 23:24 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $7.25 | $0.00 |
DisclosureSEC source: 0000874015-17-000026 · edgar.xml · derivative · entry 12 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,462 Underlying: Common Stock · 10,000 shares Expires 2019-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 12, 2017 Filed Apr 13, 2017 23:24 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 1,000 | $40.07 | $40,070.00 |
DisclosureSEC source: 0000874015-17-000026 · edgar.xml · nonDerivative · entry 4 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 3,062 F3 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 9/21/2015. F3 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 9/21/2015. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.02 to $40.08, inclusive. The reporting person's wife undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) on this Form 4. Read SEC document |
| April 12, 2017 Filed Apr 13, 2017 23:24 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 1,000 | $10.29 | $10,290.00 |
DisclosureSEC source: 0000874015-17-000026 · edgar.xml · nonDerivative · entry 3 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 4,062 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 9/21/2015. F3 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 9/21/2015. Read SEC document |
| April 12, 2017 Filed Apr 13, 2017 23:24 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 10,000 | $40.07 | $400,700.00 |
DisclosureSEC source: 0000874015-17-000026 · edgar.xml · nonDerivative · entry 2 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,014 F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 9/21/2015. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 9/21/2015. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.02 to $40.08, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| April 12, 2017 Filed Apr 13, 2017 23:24 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 10,000 | $7.25 | $72,500.00 |
DisclosureSEC source: 0000874015-17-000026 · edgar.xml · nonDerivative · entry 1 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,014 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 9/21/2015. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 9/21/2015. Read SEC document |
| March 02, 2017 Filed Mar 7, 2017 00:23 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,100 | $0.00 Strike: $10.29 | $0.00 |
DisclosureSEC source: 0000874015-17-000024 · edgar.xml · derivative · entry 7 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 1,500 Underlying: Common Stock · 1,100 shares Expires 2018-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 02, 2017 Filed Mar 7, 2017 00:23 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 11,000 | $0.00 Strike: $7.25 | $0.00 |
DisclosureSEC source: 0000874015-17-000024 · edgar.xml · derivative · entry 6 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,462 Underlying: Common Stock · 11,000 shares Expires 2019-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 02, 2017 Filed Mar 7, 2017 00:23 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 1,100 | $51.05 | $56,155.00 |
DisclosureSEC source: 0000874015-17-000024 · edgar.xml · nonDerivative · entry 4 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 3,062 F2 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 9/21/2015. F2 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 9/21/2015. Read SEC document |
| March 02, 2017 Filed Mar 7, 2017 00:23 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 1,100 | $10.29 | $11,319.00 |
DisclosureSEC source: 0000874015-17-000024 · edgar.xml · nonDerivative · entry 3 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 4,162 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 9/21/2015. F2 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 9/21/2015. Read SEC document |
| March 02, 2017 Filed Mar 7, 2017 00:23 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 11,000 | $51.05 | $561,550.00 |
DisclosureSEC source: 0000874015-17-000024 · edgar.xml · nonDerivative · entry 2 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,014 F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 9/21/2015. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 9/21/2015. Read SEC document |
| March 02, 2017 Filed Mar 7, 2017 00:23 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 11,000 | $7.25 | $79,750.00 |
DisclosureSEC source: 0000874015-17-000024 · edgar.xml · nonDerivative · entry 1 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,014 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 9/21/2015. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 9/21/2015. Read SEC document |
| January 17, 2017 Filed Jan 18, 2017 23:36 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 131 | $46.29 | $6,063.99 |
DisclosureSEC source: 0000874015-17-000013 · edgar.xml · nonDerivative · entry 16 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 3,062 F8 · kind: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice, dated January 15, 2016. F8 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice, dated January 15, 2016. Read SEC document |
| January 17, 2017 Filed Jan 18, 2017 23:36 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 142 | $46.29 | $6,573.32 |
DisclosureSEC source: 0000874015-17-000013 · edgar.xml · nonDerivative · entry 14 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 2,859 F6 · kind: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice, dated January 15, 2015. F6 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice, dated January 15, 2015. Read SEC document |
| January 17, 2017 Filed Jan 18, 2017 23:36 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 139 | $46.29 | $6,434.31 |
DisclosureSEC source: 0000874015-17-000013 · edgar.xml · nonDerivative · entry 12 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 2,638 F4 · kind: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice, dated January 15, 2014. F4 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice, dated January 15, 2014. Read SEC document |
| January 17, 2017 Filed Jan 18, 2017 23:36 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 163 | $46.29 | $7,545.43 |
DisclosureSEC source: 0000874015-17-000013 · edgar.xml · nonDerivative · entry 10 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 2,423 F10 · kind: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice, dated January 15, 2013. F10 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice, dated January 15, 2013. Read SEC document |
| January 17, 2017 Filed Jan 18, 2017 23:36 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 4,410 | $46.29 | $204,138.90 |
DisclosureSEC source: 0000874015-17-000013 · edgar.xml · nonDerivative · entry 8 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,014 F8 · kind: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice, dated January 15, 2016. F8 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice, dated January 15, 2016. Read SEC document |
| January 17, 2017 Filed Jan 18, 2017 23:36 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 3,728 | $46.29 | $172,569.12 |
DisclosureSEC source: 0000874015-17-000013 · edgar.xml · nonDerivative · entry 6 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,291 F6 · kind: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice, dated January 15, 2015. F6 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice, dated January 15, 2015. Read SEC document |
| January 17, 2017 Filed Jan 18, 2017 23:36 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 4,236 | $46.29 | $196,080.20 |
DisclosureSEC source: 0000874015-17-000013 · edgar.xml · nonDerivative · entry 4 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,144 F4 · kind: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice, dated January 15, 2014. F4 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice, dated January 15, 2014. Read SEC document |
| January 17, 2017 Filed Jan 18, 2017 23:36 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 3,008 | $46.29 | $139,237.31 |
DisclosureSEC source: 0000874015-17-000013 · edgar.xml · nonDerivative · entry 2 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,568 F2 · kind: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice, dated January 30, 2013. F2 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice, dated January 30, 2013. Read SEC document |
| January 15, 2017 Filed Jan 18, 2017 23:36 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionRestricted Stock Units · Derivative | 334 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-17-000013 · edgar.xml · derivative · entry 27 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 999 Underlying: Common Stock · 334 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F8 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice, dated January 15, 2016. F14 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F14 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| January 15, 2017 Filed Jan 18, 2017 23:36 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionRestricted Stock Units · Derivative | 363 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-17-000013 · edgar.xml · derivative · entry 26 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 724 Underlying: Common Stock · 363 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F6 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice, dated January 15, 2015. F14 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F14 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.